San Francisco-based value-oriented investment manager specializing in long-only equity, fixed income and balanced strategies for institutional and retail clients. Dodge & Cox emphasizes bottom-up fundamental research, deep-conviction portfolios and a disciplined contrarian approach to valuation and risk. Known for low-turnover, concentrated holdings and multi-decade continuity in senior investment teams, the firm competes with global active managers in the value and income segments.
San Francisco-based value-oriented investment manager specializing in long-only equity, fixed income and balanced strategies for institutional and retail clients. Dodge & Cox emphasizes bottom-up fundamental research, deep-conviction portfolios and a disciplined contrarian approach to valuation and risk. Known for low-turnover, concentrated holdings and multi-decade continuity in senior investment teams, the firm competes with global active managers in the value and income segments.
Value-driven, long-term capital allocator focused on high-conviction, low-turnover equity and fixed-income positions across institutional and retail mandates. Investment decisions are grounded in bottom-up fundamental research, rigorous valuation discipline and a contrarian lens that seeks mispriced securities and durable cash flows. Portfolios emphasize concentrated holdings, income generation and risk control via duration and quality selection in credit. Governance favors team continuity, internal accountability and an underwriting bias toward deep research edge rather than market timing.
Value-driven, long-term capital allocator focused on high-conviction, low-turnover equity and fixed-income positions across institutional and retail mandates. Investment decisions are grounded in bottom-up fundamental research, rigorous valuation discipline and a contrarian lens that seeks mispriced securities and durable cash flows. Portfolios emphasize concentrated holdings, income generation and risk control via duration and quality selection in credit. Governance favors team continuity, internal accountability and an underwriting bias toward deep research edge rather than market timing.
| Trades 17476 | Longs Won 12381/17476 70% | Profit Factor 3.65 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $78.69M |
| Average Win $23.44M | Best Trade (Oct 15) $1.69B | Sharpe Ratio -28.52 |
| Average Loss -$15.58M | Worst Trade (Mar 31) -$1.48B | Z-Score -9.63 (100%) |
| Commissions $0 | Avg. Trade Length 4y 6m 3w 1d | Expectancy $12.06M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 12,821 | 11,538 | 10,256 | 8,974 | 7,692 | 6,410 | 5,128 | 3,846 | 2,564 | 1,282 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 31,382 | $3.28M | $10.82M | - | $7.54M | 230.28% | +1.552% |
ABBV AbbVie Inc. | 10,393 | $553,384.54 | $2.95M | - | $2.39M | 432.48% | -1.922% |
ABEV Ambev S.A. ADR | 252,700 | $522,653 | $827,592.5 | - | $304,939.5 | 58.34% | -1.355% |
ABT Abbott Laboratories | 17,324 | $755,673.11 | $1.72M | - | $960,269.09 | 127.07% | -3.319% |
ACMR ACM Research, Inc. Class A Common Stock | 116,392 | $3.37M | $6.43M | - | $3.06M | 90.97% | +0.528% |
ADBE Adobe Inc. | 3.11M | $963.9M | $795.49M | - | -$168.4M | -17.47% | -0.526% |
ADI Analog Devices, Inc. | 19,210 | $3.22M | $7.82M | - | $4.6M | 143.13% | +2.549% |
ADM Archer-Daniels-Midland Company | 14.18M | $817.33M | $1.12B | - | $304.77M | 37.29% | -1.665% |
AEG Aegon Ltd. New York Registry Shares | 44.64M | $257.18M | $375.38M | - | $118.2M | 45.96% | +1.082% |
AEP American Electric Power Company, Inc. | 8.67M | $747.63M | $1.11B | - | $360.87M | 48.27% | +0.448% |
AFYA Afya Ltd Class A Common Shares | 51,287 | $696,878.82 | $769,305 | - | $72,426.18 | 10.39% | -0.662% |
AJG Arthur J. Gallagher & Co. | 9.36M | $2.09B | $2.42B | - | $328.32M | 15.7% | -0.332% |
ALL The Allstate Corporation | 2,595 | $102,776.88 | $648,555.37 | - | $545,778.49 | 531.03% | +0.006% |
ALNY Alnylam Pharmaceuticals, Inc. | 1.96M | $280.54M | $443.86M | - | $163.33M | 58.22% | -1.61% |
AMG Affiliated Managers Group, Inc. | 600 | $203,040 | $237,360 | - | $34,320 | 16.9% | +1.762% |
AMGN Amgen Inc. Common Stock | 12,817 | $781,000.88 | $5.61M | - | $4.83M | 618.37% | -0.273% |
AMP Ameriprise Financial Inc. | 1,500 | $78,248.78 | $737,145 | - | $658,896.22 | 842.05% | +0.771% |
AMZN Amazon.com Inc | 16.71M | $1.9B | $4.4B | - | $2.51B | 132.08% | +0.358% |
AON Aon plc Class A | 8.59M | $3.03B | $2.53B | - | -$495.41M | -16.37% | -0.704% |
APA APA Corporation | 19,500 | $349,049.79 | $971,782.5 | - | $622,732.71 | 178.41% | -0.13% |